Emerging infectious disease detection technologies encompass molecular diagnostics, immunological assays, and next-generation sequencing platforms that enable rapid identification of novel pathogens such as SARS-CoV-2, avian influenza, Mpox virus, and other newly recognized threats. This technical article systematically reviews detection principles, sample types, testing items, analytical methods, quality standards, and practical applications for accredited third-party laboratories, clinical institutions, and public health agencies.
Technical Overview
Emerging infectious diseases (EIDs) are infections that have newly appeared in a human population or have existed previously but are rapidly increasing in incidence or geographic range, as defined by the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC). Representative examples include COVID-19 (SARS-CoV-2), Middle East respiratory syndrome (MERS), Ebola virus disease, Zika virus infection, Nipah virus encephalitis, highly pathogenic avian influenza (H5N1, H7N9), Mpox (mpox virus), and novel hantavirus infections. Because EIDs often present with non-specific symptoms and lack established diagnostic assays at the time of emergence, rapid, sensitive, and scalable detection technology is the cornerstone of outbreak control.
Modern EID detection technology is built on four analytical pillars: nucleic acid amplification tests (NAAT) such as real-time PCR and isothermal amplification; immunodiagnostics including antigen and antibody assays; metagenomic and targeted next-generation sequencing (NGS) for pathogen discovery and genomic surveillance; and biosensor or microfluidic platforms designed for point-of-care (POC) deployment. Performance is characterized by analytical sensitivity (limit of detection, LoD), analytical specificity (inclusivity and exclusivity), clinical sensitivity and specificity, turnaround time (TAT), throughput, multiplexing capacity, and biosafety compatibility.
Quality management for EID testing laboratories is governed by internationally recognized frameworks, including ISO 15189 for medical laboratory competence, ISO/IEC 17025 for general testing laboratory accreditation, ISO 13485 for in vitro diagnostic (IVD) device manufacturing, ISO 20395 for biotechnology performance evaluation of qualitative measurement methods, and ISO 15190 together with biosafety standards such as GB 19489 for laboratory biosafety requirements. Clinical and Laboratory Standards Institute (CLSI) guidelines, including CLSI MM3 for molecular diagnostic methods, further support method validation and verification.
Testing Samples
Respiratory Tract Samples
Respiratory specimens are the primary matrix for airborne and droplet-transmitted pathogens. Accepted sample types include nasopharyngeal and oropharyngeal swabs, nasal aspirates and washes, sputum, endotracheal aspirates, and bronchoalveolar lavage (BAL) fluid. Swabs should be collected with flocked synthetic (nylon or polyester) applicators and placed in viral transport medium (VTM) or universal transport medium (UTM) to preserve nucleic acid integrity during cold-chain shipment, typically at 2–8 °C for 48–72 hours or frozen at −70 °C or below for extended storage.
Blood and Serum Samples
EDTA anticoagulated whole blood and plasma are used for molecular detection of systemic viruses (for example, Ebola virus, Mpox virus, and arboviruses), while serum is the preferred matrix for serological testing, including IgM, IgG, total antibody, and neutralizing antibody assays. Blood samples for molecular testing should be processed within 24 hours or stored at −70 °C; serum for serology may be held at 2–8 °C for up to several days before freezing.
Fecal and Gastrointestinal Samples
Stool specimens are essential for emerging enteric viruses such as novel norovirus strains, rotavirus variants, and enteric coronaviruses, as well as for pathogen shedding studies in respiratory viruses such as SARS-CoV-2. Rectal swabs are acceptable alternatives when stool collection is impractical. Samples are transported at 2–8 °C and nucleic acid extraction is performed with inhibitors-removal protocols to counteract PCR inhibition by fecal matrix components.
Cerebrospinal Fluid and Sterile Body Fluids
Cerebrospinal fluid (CSF), pleural fluid, pericardial fluid, synovial fluid, and amniotic fluid are tested for emerging neurotropic pathogens such as Nipah virus, Zika virus, Japanese encephalitis virus, and tick-borne encephalitis virus. Strict aseptic collection, immediate transport at 2–8 °C, and preferential use of high-sensitivity methods such as nested PCR, real-time PCR, or metagenomic NGS are recommended due to typically low pathogen loads.
Tissue and Biopsy Samples
Fresh-frozen tissue, formalin-fixed paraffin-embedded (FFPE) blocks, and fine-needle aspirates are analyzed for emerging pathogens in severe or fatal cases, including myocarditis-associated viruses and vasculotropic rickettsiae. FFPE material requires specialized deparaffinization and short-amplicon assay design to compensate for formalin-induced nucleic acid fragmentation.
Environmental, Vector, and Animal Reservoir Samples
Under the One Health paradigm, EID surveillance extends to wastewater and sewage samples, surface and air environmental swabs, arthropod vectors such as mosquitoes and ticks, and wildlife or livestock reservoir specimens including oral swabs, cloacal swabs, and organ tissues from poultry in avian influenza monitoring. These matrices support early warning systems independent of clinical case detection.
Testing Items
Detection portfolios for emerging infectious diseases are structured around the analyte class and the diagnostic objective, as summarized below.
- Pathogen nucleic acid detection (qualitative): species- or genotype-specific real-time PCR and RT-PCR assays confirming the presence of viral, bacterial, or parasitic genomic material.
- Quantitative nucleic acid testing (viral load): determination of copies per milliliter for disease staging, therapeutic monitoring, and infectivity assessment.
- Antigen detection: rapid identification of viral proteins such as SARS-CoV-2 nucleocapsid or influenza virus nucleoprotein using lateral-flow immunochromatography or chemiluminescence.
- Antibody and serology panels: IgM for recent infection, IgG for past exposure and seroprevalence, total antibody assays, and surrogate or live-virus neutralization tests for immune response evaluation.
- Multiplex syndromic panels: simultaneous detection of 20–40 or more respiratory, gastrointestinal, or CNS pathogens to differentiate emerging agents from endemic circulating strains.
- Whole-genome sequencing and variant surveillance: identification of spike or polymerase gene mutations, lineage assignment, and phylogenetic analysis for outbreak source tracing.
- Antimicrobial and antiviral resistance markers: detection of resistance-associated genes or mutations guiding therapy in bacterial co-infections and chronic viral infections.
- Pathogen isolation and characterization: virus culture in qualified cell lines performed only in laboratories meeting the corresponding biosafety level requirements, followed by electron microscopy or immunofluorescence confirmation.
- Genotyping and clonality analysis: multilocus sequence typing (MLST) and single-nucleotide polymorphism (SNP) analysis for newly emerged bacterial pathogens.
Testing Methods
Method selection balances analytical performance, turnaround time, throughput, biosafety constraints, and the availability of validated commercial or laboratory-developed tests (LDTs). The principal technology platforms are described below.
Real-Time PCR and RT-PCR
Real-time quantitative PCR using hydrolysis (TaqMan) probes targeting conserved genomic regions remains the reference standard for EID confirmation. Assays demonstrate typical analytical sensitivity at the level of tens of genome copies per reaction with turnaround times of 2–4 hours. Cycle threshold (Ct) values provide semi-quantitative interpretation, and dual-target designs mitigate false-negative results caused by primer–probe site mutations. During the COVID-19 pandemic, WHO and CDC real-time RT-PCR protocols were deployed globally within weeks of genome publication, demonstrating the central role of this platform in outbreak response.
Isothermal Amplification Methods
Loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), and helicase-dependent amplification (HDA) amplify nucleic acids at a constant temperature of 37–65 °C, eliminating thermocycling instrumentation. Colorimetric or fluorescent readout enables results in 20–60 minutes, making these methods well suited to field hospitals, border screening points, and resource-limited settings.
Digital PCR (dPCR)
Droplet or chip-based digital PCR partitions reactions into thousands of individual compartments, enabling absolute quantification without calibration curves, enhanced tolerance to inhibitors, and improved sensitivity for low-titer specimens. dPCR serves as a reference method for viral load standardization and assay LoD determination.
Metagenomic Next-Generation Sequencing (mNGS)
Shotgun metagenomic sequencing applied directly to clinical samples permits culture-free, hypothesis-free pathogen discovery. mNGS was pivotal in identifying the novel Bunyavirus responsible for severe fever with thrombocytopenia syndrome and continues to serve as the definitive tool for unexplained encephalitis, pneumonia, and sepsis workups. Rigorous contamination control, human DNA or RNA depletion, and bioinformatics pipelines with curated pathogen databases are essential, and method performance should align with ISO 20395 requirements for qualitative measurement procedures.
Targeted NGS and Amplicon-Based Sequencing
Multiplex PCR amplicon sequencing and hybrid-capture panels, such as tiled SARS-CoV-2 whole-genome schemes, deliver cost-effective genomic surveillance at population scale with rapid turnaround, supporting variant-of-concern monitoring and molecular epidemiology.
CRISPR-Based Diagnostics
CRISPR-Cas12 and Cas13 systems combined with isothermal pre-amplification achieve near-PCR sensitivity with lateral-flow or fluorescent readout in under one hour. Collateral cleavage of reporter molecules provides single-base mismatch discrimination, enabling field-deployable genotyping of emerging variants.
Serological and Immunoassay Platforms
Enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CLIA), immunofluorescence assay (IFA), and rapid lateral-flow antigen tests cover the antibody and antigen testing spectrum. High-throughput CLIA platforms process hundreds of samples per hour for seroprevalence studies, while point-of-care antigen tests provide 15–30 minute screening despite lower analytical sensitivity, requiring confirmatory NAAT for negative results in high-prevalence settings.
Mass Spectrometry and Biosensors
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) accelerates identification of newly emerged bacterial pathogens from culture, and surface plasmon resonance or electrochemical biosensors offer label-free, real-time pathogen detection with emerging applications in environmental monitoring.
Virus Isolation and Electron Microscopy
Cell culture isolation remains the phenotypic reference for viability determination but is restricted to high-containment facilities, for example Biosafety Level 3 or 4 laboratories, in accordance with ISO 15190 and national biosafety regulations such as GB 19489. Negative-stain and cryo-electron microscopy provide morphological characterization supporting novel agent identification.
Applications
Detection technologies for emerging infectious diseases support a broad spectrum of clinical and public health missions.
- Clinical diagnosis and triage: rapid etiological confirmation guiding isolation, antiviral or antibiotic therapy, and severity risk stratification in emergency and inpatient settings.
- Outbreak investigation and response: case confirmation, contact tracing, transmission chain reconstruction, and evaluation of containment measures during cluster and epidemic events.
- Genomic surveillance: systematic sequencing to detect variants of concern, monitor mutational trajectories, and inform vaccine antigen updates in alignment with WHO global surveillance networks.
- Wastewater-based epidemiology: community-level early warning of pathogen circulation, including poliovirus, SARS-CoV-2, and influenza, one to two weeks ahead of clinical case reporting.
- Border and port health screening: point-of-care testing at airports, land crossings, and quarantine facilities to reduce international spread risk.
- Pandemic preparedness: assay development pipelines, external quality assessment (EQA) programs, and reagent stockpiles enabling deployment of validated tests within days of novel pathogen sequence release.
- One Health surveillance: monitoring of animal reservoirs, poultry populations, and arthropod vectors to identify zoonotic spillover risk before human transmission occurs.
- Vaccine and therapeutics evaluation: immunogenicity testing, neutralizing antibody quantification, and virological endpoints in clinical trials.
- Research and reference services: accredited third-party laboratories provide method development, validation, and confirmatory testing for manufacturers, research institutions, and government agencies.
FAQ
What is an emerging infectious disease? An emerging infectious disease is an infection whose incidence in humans has increased within the past two decades or threatens to increase in the near future, including newly recognized agents such as SARS-CoV-2 and Mpox virus as well as known pathogens expanding into new geographic regions or host populations.
How quickly can test results be obtained? Turnaround times vary by platform: rapid antigen tests deliver results in 15–30 minutes, real-time PCR in 2–4 hours from extracted sample, isothermal and CRISPR assays in 30–60 minutes, and mNGS workflows in 24–48 hours including bioinformatics analysis.
Which method offers the highest sensitivity? Real-time PCR and digital PCR generally provide the lowest limits of detection among routine assays, while mNGS offers the broadest unbiased coverage; the optimal choice depends on clinical context, pathogen load, and specificity requirements.
What are the differences between nucleic acid, antigen, and antibody testing? Nucleic acid tests detect current pathogen genetic material with high sensitivity; antigen tests detect viral proteins quickly but with lower sensitivity; antibody tests indicate immune response and past exposure but may be negative during early infection due to seroconversion delay.
What biosafety measures are required? Non-propagative molecular testing of routine specimens may be performed with good laboratory practice and risk assessment under ISO 15190, whereas virus culture and manipulation of high-consequence pathogens require Biosafety Level 3 or 4 containment in compliance with national regulations such as GB 19489.
Which quality standards apply to EID testing laboratories? Accredited third-party laboratories operate under ISO/IEC 17025 or ISO 15189 quality management systems, validate methods according to ISO 20395 and CLSI guidelines, use IVD reagents manufactured under ISO 13485, and participate in external quality assessment and proficiency testing programs.
How should specimens be transported? Specimens must be packaged in accordance with UN 3373 biological substance Category B requirements, maintained under validated cold-chain conditions, and accompanied by complete chain-of-custody documentation to preserve nucleic acid and antigen integrity.
